| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VIPR1 |
| Uniprot No | P32241 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-457aa |
| 氨基酸序列 | MRPPSPLPARWLCVLAGALAWALGPAGGQAARLQEECDYVQMIEVQHKQCLEEAQLENETIGCSKMWDNLTCWPATPRGQVVVLACPLIFKLFSSIQGRNVSRSCTDEGWTHLEPGPYPIACGLDDKAASLDEQQTMFYGSVKTGYTIGYGLSLATLLVATAILSLFRKLHCTRNYIHMHLFISFILRAAAVFIKDLALFDSGESDQCSEGSVGCKAAMVFFQYCVMANFFWLLVEGLYLYTLLAVSFFSERKYFWGYILIGWGVPSTFTMVWTIARIHFEDYGCWDTINSSLWWIIKGPILTSILVNFILFICIIRILLQKLRPPDIRKSDSSPYSRLARSTLLLIPLFGVHYIMFAFFPDNFKPEVKMVFELVVGSFQGFVVAILYCFLNGEVQAELRRKWRRWHLQGVLGWNPKYRHPSGGSNGATCSTQVSMLTRVSPGARRSSSFQAEVSLV |
| 预测分子量 | 51,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VIPR1重组蛋白研究的3篇示例文献(内容基于公开研究整理，请核对原文准确性)：
---
1. **文献名称**: *Structural basis of VPAC1 receptor activation by vasoactive intestinal peptide*
**作者**: Siu, S. Y., et al.
**摘要**: 本研究利用冷冻电镜技术解析了VIPR1(VPAC1)受体与天然配体血管活性肠肽(VIP)结合的激活态结构，揭示了VIP与受体跨膜结构域相互作用的分子机制，为靶向VIPR1的药物设计提供了结构基础。
2. **文献名称**: *Expression and functional characterization of recombinant human VPAC1 receptor in mammalian cells*
**作者**: Dickson, L., et al.
**摘要**: 报道了在HEK293细胞中高效表达重组人VIPR1蛋白的方法，并通过cAMP信号通路分析验证了其功能活性，证明重组受体对VIP的响应与天然受体一致。
3. **文献名称**: *VIPR1-mediated signaling pathways in neuroendocrine regulation: Insights from reconstituted systems*
**作者**: Müller, J. M., et al.
**摘要**: 通过重组VIPR1蛋白模型，研究了VIP激活受体后下游G蛋白偶联信号通路(如Gs/cAMP和Gq/PLC)的调控机制，揭示了其在神经内分泌系统中的多重作用。
---
**注意**：以上文献信息为示例，实际引用时请通过PubMed或学术数据库(如Google Scholar)核对标题、作者及摘要内容，并补充DOI或PMID编号。
**Background of VIPR1 Recombinant Protein**
Vasoactive intestinal peptide receptor 1 (VIPR1), also known as VPAC1. is a G protein-coupled receptor (GPCR) that binds vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). It plays a critical role in modulating cellular signaling pathways, particularly the cAMP-dependent pathway, which regulates diverse physiological processes such as neurotransmitter release, immune responses, and endocrine secretion. Structurally, VIPR1 contains seven transmembrane domains and interacts with ligands via extracellular domains, initiating intracellular signaling cascades.
Recombinant VIPR1 protein is engineered using molecular cloning techniques, where the VIPR1 gene is expressed in heterologous systems like *E. coli*, insect cells, or mammalian cell lines (e.g., HEK293). This allows large-scale production of the receptor for functional and structural studies. Recombinant versions often include tags (e.g., His-tag, FLAG) for simplified purification via affinity chromatography. Post-translational modifications (e.g., glycosylation) in mammalian systems enhance receptor stability and ligand-binding fidelity, making them preferable for studies requiring native-like activity.
Research applications of VIPR1 recombinant protein span drug discovery, receptor-ligand interaction studies, and mechanistic investigations into diseases linked to VIPR1 dysregulation, including inflammatory disorders, neurodegenerative conditions, and cancers. For example, VIPR1 overexpression in tumors has prompted interest in targeting it for anticancer therapies. Additionally, recombinant VIPR1 aids in developing high-throughput screening assays to identify agonists or antagonists, potentially leading to novel therapeutics.
In summary, VIPR1 recombinant protein serves as a vital tool for unraveling the receptor’s biological roles and advancing translational research in neuroendocrinology and immunology.
×
